Dr. Barbara J. Baxter, MD
Allergy & Immunology (Allergy & Immunology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Columbia University College of Physicians and Surgeons (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 238
Licensed in Texas since 1980, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: Columbia University College of Physicians and Surgeons
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology (Internal Medicine) Physician primary
TX license F7931 (first issued 1980; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 238
- Services billed
- 28,484
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 6,770 | 15 |
| Test for allergy using allergenic extract | 4,948 | 63 |
| Professional service for preparation and provision of 1 or more antigens | 4,047 | 125 |
| Injection, immune globulin (bivigam), 500 mg | 2,140 | 16 |
| Professional service for multiple injections of allergen | 2,104 | 127 |
| Test for allergy using allergenic extract injected into skin | 1,111 | 58 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 208 | 16 |
| Professional service for single injection of allergen | 172 | 17 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 164 | 17 |
| Established patient office or other outpatient visit, 40-54 minutes | 128 | 88 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Dallas, TX | 235 |
| Fluticasone Propionate Other prescribers in Dallas, TX | 55 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Dallas, TX | 53 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Dallas, TX | 49 |
| Azithromycin Other prescribers in Dallas, TX | 42 |
| Wixela Inhub (fluticasone propion/salmeterol) Other prescribers in Dallas, TX | 39 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Dallas, TX | 34 |
| Azelastine Hcl Other prescribers in Dallas, TX | 33 |
| Prednisone Other prescribers in Dallas, TX | 31 |
| Epinephrine Other prescribers in Dallas, TX | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 31 payments worth $716 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $104 |
|---|---|
| Octapharma USA, Inc. | $91.86 |
| Pfizer Inc. | $77.81 |
| Regeneron Healthcare Solutions, Inc. | $68.84 |
| Amgen Inc. | $60.08 |
| Azurity Pharmaceuticals, Inc. | $59.93 |
| Grifols USA, LLC | $48.15 |
| Takeda Pharmaceuticals U.S.A., Inc. | $44.80 |
| Food and Beverage | $682 |
|---|---|
| Education | $34.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Aug 12, 2025 | Education in-kind | $34.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $521,817 in research payments for these studies, mostly to the institutions running them.
- A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - A phase 4, 52-week (primary analysis at 24-weeks), randomized, stratif
GlaxoSmithKline, LLC. - A phase 2 randomized doubleblind placebocontrolled parallelgroup doseranging study to investigate the efficacy and safety of PF07275315 in adult participants with inadequately controlled moderatetosevere asthma
Pfizer Inc. - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc. - A phase 3 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in migraine prevention in children and adolescents 6 to 18 years of age
Pfizer Inc. - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - A multi-centre, single arm, open-label extension study to evaluate the
GlaxoSmithKline, LLC. - A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine
Merz Pharmaceuticals, LLC - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.